Market Summary
USD8.40+0.18
Market Closed2.19%
ADPT Stock Price
ADPT RSI Chart
ADPT Valuation
ADPT Price/Sales (Trailing)
ADPT Profitability
ADPT Fundamentals
ADPT Revenue
ADPT Earnings
Price Action
52 Week Range
5.9615.19
(Low)(High)
Last 7 days
-7.5%
Last 30 days
-5.4%
Last 90 days
1.1%
Trailing 12 Months
-23.5%
ADPT Financial Health
ADPT Investor Care
Peers (Alternatives to Adaptive BioTech)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 40.4B | 6.8B | -13.31% | 3.22% | 32.19 | 5.89 | 8.37% | 3.64% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
MTD | 32.5B | 3.9B | -7.42% | 9.05% | 37.3 | 8.3 | 5.43% | 13.46% |
TECH | 11.5B | 1.1B | -5.60% | -27.97% | 44.06 | 10.31 | 8.77% | 24.82% |
| MID-CAP | ||||||||
RGEN | 9.7B | 801.5M | -9.29% | 0.51% | 52.37 | 12.15 | 19.54% | 44.95% |
| SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | -11.70% | -1.09% | -6.37 | 15.61 | -1.69% | -73.40% |
ADPT | 1.2B | 185.3M | -5.41% | -23.53% | -6 | 6.49 | 20.06% | 3.42% |
QTRX | 450.3M | 105.5M | -12.44% | -50.56% | -4.66 | 4.27 | -4.55% | -67.63% |
NSTG | 405.5M | 127.3M | -23.43% | -69.17% | -2.54 | 3.19 | -12.28% | -38.43% |
BNGO | 341.8M | 27.8M | -23.57% | -31.43% | -2.58 | 12.29 | 54.62% | -83.06% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
CDXC | 121.5M | 72.0M | -9.68% | -16.83% | -7.37 | 1.69 | 6.82% | 39.11% |
HBIO | 117.4M | 113.3M | -15.92% | -55.18% | -12.34 | 1.04 | -4.68% | -3204.17% |
CSBR | 54.2M | 54.1M | -0.24% | -45.98% | 502.17 | 1 | 21.80% | -72.38% |
Financials for Adaptive BioTech
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 10.3% | 185,308,000 | 168,040,000 | 159,677,000 | 154,522,000 | 154,344,000 |
| S&GA Expenses | -3.0% | 95,603,000 | 98,583,000 | 102,019,000 | 100,954,000 | 95,465,000 |
| R&D Expenses | -2.4% | 141,756,000 | 145,233,000 | 145,647,000 | 146,410,000 | 142,343,000 |
| EBITDA | 1.2% | -190,369,000 | -192,659,000 | - | - | - |
| EBITDA Margin | 4.4% | -1.19 | -1.25 | - | - | - |
| Earnings Before Taxes | - | -207,298,000 | - | - | - | - |
| EBT Margin | 3.2% | -1.30 | -1.34 | - | - | - |
| Interest Expenses | 62.3% | 4,238,000 | 2,612,000 | - | - | - |
| Net Income | 9.6% | -200,191,000 | -221,496,000 | -232,118,000 | -236,070,000 | -207,279,000 |
| Net Income Margin | 18.0% | -1.08 | -1.32 | -1.45 | -1.48 | - |
| Free Cahsflow | 13.2% | -200,294,000 | -230,804,000 | -241,026,000 | -247,917,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -3.1% | 857 | 884 | 807 | 858 | 923 |
| Current Assets | -0.4% | 562 | 564 | 439 | 419 | 403 |
| Cash Equivalents | -58.6% | 90.00 | 218 | 76.00 | 115 | 139 |
| Inventory | -16.7% | 14.00 | 17.00 | 19.00 | 21.00 | 19.00 |
| Net PPE | -3.7% | 83.00 | 87.00 | 87.00 | 86.00 | 85.00 |
| Goodwill | 0% | 119 | 119 | 119 | 119 | 119 |
| Liabilities | -1.0% | 393 | 396 | 288 | 305 | 319 |
| Current Liabilities | 5.5% | 110 | 104 | 111 | 115 | 114 |
| Shareholder's Equity | -4.9% | 464 | 488 | 518 | 553 | 604 |
| Retained Earnings | -4.6% | -919 | -878 | -833 | -781 | -718 |
| Additional Paid-In Capital | 1.1% | 1,387 | 1,373 | 1,358 | 1,340 | 1,324 |
| Accumulated Depreciation | - | 36.00 | - | - | - | - |
| Shares Outstanding | 0.1% | 143 | 143 | 143 | 142 | 141 |
| Minority Interest | -157.7% | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 11.5% | -183 | -207 | -208 | -198 | -192 |
| Share Based Compensation | 4.6% | 55.00 | 53.00 | 51.00 | 48.00 | 43.00 |
| Cashflow From Investing | -98.3% | 3.00 | 168 | 88.00 | 125 | 181 |
| Cashflow From Financing | -2.4% | 132 | 136 | 13.00 | 15.00 | 27.00 |
Risks for ADPT
What is the probability of a big loss on ADPT?
98.5%
Probability that Adaptive BioTech stock will be more than 20% underwater in next one year
92.3%
Probability that Adaptive BioTech stock will be more than 30% underwater in next one year.
90.8%
Probability that Adaptive BioTech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ADPT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.
Drawdowns
Returns for ADPT
Cumulative Returns on ADPT
-25.3%
3-Year Cumulative Returns
Which funds bought or sold ADPT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.04 | 8,407 | 121,407 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -5.96 | 11,000 | 1,271,000 | 0.01% |
2023-03-03 | TIAA, FSB | reduced | -14.83 | -16,471 | 175,529 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 22,444 | 329,444 | -% |
2023-02-22 | CVA Family Office, LLC | unchanged | - | 247 | 3,247 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -24.51 | -111,000 | 442,000 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | unchanged | - | -183 | 817 | -% |
2023-02-15 | CAPTRUST FINANCIAL ADVISORS | sold off | -100 | -88,000 | - | -% |
2023-02-15 | Cerity Partners LLC | reduced | -0.2 | 80,144 | 1,209,140 | 0.01% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -46.28 | -1,148,000 | 1,563,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Adaptive BioTech News
Schedule 13G FIlings of Adaptive BioTech
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | blackrock inc. | 8.7% | 12,374,197 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.25% | 11,794,168 | SC 13G/A | |
| Sep 12, 2022 | price t rowe associates inc /md/ | 2.9% | 4,081,518 | SC 13G/A | |
| Feb 14, 2022 | matrix capital management company, lp | 8.20% | 11,572,590 | SC 13G/A | |
| Feb 14, 2022 | viking global investors lp | 21.3% | 29,993,708 | SC 13G/A | |
| Feb 10, 2022 | price t rowe associates inc /md/ | 10.0% | 14,240,614 | SC 13G/A | |
| Feb 10, 2022 | price t rowe associates inc /md/ | 9.4% | 13,286,713 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 7.82% | 11,031,288 | SC 13G/A | |
| Feb 16, 2021 | viking global investors lp | 21.9% | 29,993,708 | SC 13G/A | |
| Feb 16, 2021 | matrix capital management company, lp | 9.59% | 13,115,090 | SC 13G/A |
ADPT Fair Value
Adaptive BioTech fair value in different scenarios
The table shows the Fair Value estimates for Adaptive BioTech for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 0.90 -89.29% | 1.11 -86.79% | 1.71 -79.64% | 2.82 -66.43% | 4.33 -48.45% |
| Current Inflation | 0.89 -89.40% | 1.07 -87.26% | 1.60 -80.95% | 2.56 -69.52% | 3.85 -54.17% |
| Very High Inflation | 0.87 -89.64% | 1.03 -87.74% | 1.47 -82.50% | 2.25 -73.21% | 3.30 -60.71% |
Historical Adaptive BioTech Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Adaptive BioTech
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for ADPT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-07 | Taylor Stacy L | sold | -115,128 | 8.6 | -13,387 | svp and general counsel |
2023-03-07 | ADAMS R MARK | sold | -147,533 | 8.6 | -17,155 | chief operating officer |
2023-03-07 | SOOD NITIN | sold | -84,391 | 8.6 | -9,813 | chief commercial officer, mrd |
2023-03-06 | Taylor Stacy L | sold | -47,057 | 8.57 | -5,491 | svp and general counsel |
2023-03-06 | Conroy Kevin T | acquired | - | - | 14,775 | - |
2023-03-06 | LO FRANCIS | sold | -58,413 | 8.57 | -6,816 | chief people officer |
2023-03-06 | ADAMS R MARK | acquired | - | - | 88,652 | chief operating officer |
2023-03-06 | ROBINS HARLAN S | acquired | - | - | 354,610 | chief scientific officer |
2023-03-06 | HERSHBERG ROBERT | acquired | - | - | 14,775 | - |
2023-03-06 | LO FRANCIS | acquired | - | - | 85,697 | chief people officer |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
ADPT Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenue | |||
| Revenue | $ 185,308 | $ 154,344 | $ 98,382 |
| Operating expenses | |||
| Cost of revenue | 57,909 | 49,301 | 22,530 |
| Research and development | 141,756 | 142,343 | 116,072 |
| Sales and marketing | 95,603 | 95,465 | 61,358 |
| General and administrative | 88,527 | 74,502 | 49,536 |
| Amortization of intangible assets | 1,699 | 1,699 | 1,703 |
| Total operating expenses | 385,494 | 363,310 | 251,199 |
| Loss from operations | (200,186) | (208,966) | (152,817) |
| Interest and other income, net | 4,056 | 1,668 | 6,590 |
| Interest expense | (4,238) | ||
| Net loss | (200,368) | (207,298) | (146,227) |
| Add: Net loss attributable to noncontrolling interest | 177 | 19 | |
| Net loss attributable to Adaptive Biotechnologies Corporation | $ (200,191) | $ (207,279) | $ (146,227) |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $ (1.40) | $ (1.48) | $ (1.11) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | 142,515,917 | 140,354,915 | 131,216,468 |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $ (1.40) | $ (1.48) | $ (1.11) |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | 142,515,917 | 140,354,915 | 131,216,468 |
ADPT Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 90,030,000 | $ 139,065,000 |
| Short-term marketable securities (amortized cost of $412,282 and $214,115, respectively) | 408,166,000 | 213,996,000 |
| Accounts receivable, net | 40,057,000 | 17,409,000 |
| Inventory | 14,453,000 | 19,263,000 |
| Prepaid expenses and other current assets | 9,440,000 | 13,015,000 |
| Total current assets | 562,146,000 | 402,748,000 |
| Long-term assets | ||
| Property and equipment, net | 83,447,000 | 85,262,000 |
| Operating lease right-of-use assets | 80,763,000 | 87,678,000 |
| Long-term marketable securities (amortized cost of $218,163) | 217,145,000 | |
| Restricted cash | 2,398,000 | 2,138,000 |
| Intangible assets, net | 6,827,000 | 8,526,000 |
| Goodwill | 118,972,000 | 118,972,000 |
| Other assets | 2,064,000 | 875,000 |
| Total assets | 856,617,000 | 923,344,000 |
| Current liabilities | ||
| Accounts payable | 8,084,000 | 3,307,000 |
| Accrued liabilities | 12,424,000 | 9,343,000 |
| Accrued compensation and benefits | 15,935,000 | 15,642,000 |
| Current portion of operating lease liabilities | 9,230,000 | 5,055,000 |
| Current deferred revenue | 64,115,000 | 80,460,000 |
| Total current liabilities | 109,788,000 | 113,807,000 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 98,772,000 | 106,685,000 |
| Deferred revenue, less current portion | 58,599,000 | 98,750,000 |
| Revenue interest liability, net | 125,360,000 | |
| Total liabilities | 392,519,000 | 319,242,000 |
| Commitments and contingencies (Note 12) | ||
| Shareholders’ equity | ||
| Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021 | ||
| Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2022 and 2021; 143,105,002 and 141,393,865 shares issued and outstanding at December 31, 2022 and 2021, respectively | 14,000 | 14,000 |
| Additional paid-in capital | 1,387,349,000 | 1,324,006,000 |
| Accumulated other comprehensive loss | (4,116,000) | (1,137,000) |
| Accumulated deficit | (919,082,000) | (718,891,000) |
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 464,165,000 | 603,992,000 |
| Noncontrolling interest | (67,000) | 110,000 |
| Total shareholders’ equity | 464,098,000 | 604,102,000 |
| Total liabilities and shareholders’ equity | $ 856,617,000 | $ 923,344,000 |